By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
LSN is proud to announce our partnership with Enterprise SG for RESI JPM 2026, to foster meaningful conversations on global life science innovation, investment and cross-border collaboration. Learn how Singapore is a dynamic launchpad for innovation and home to cutting-edge startups ready to collaborate on your next breakthrough. Join us at our upcoming panel on January 12 to find out more!
As global healthcare challenges intensify, innovative biomedical technologies from Asia are stepping up to drive change, translating life science research into real-world solutions. Increasingly, investors, corporates, startups, and healthcare systems around the world are seeing the urgency in bridging the East and West to improve healthcare outcomes and deliver value-based care.
Singapore, located at the heart of Asia, is a dynamic hub for biomedical innovation, driven by a strong network of global investors, researchers, mentors, and innovators. With decades of sustained government investments and a robust talent pipeline from world-class universities and research institutes, it is home to over 500 biomedical and medtech companies. The ecosystem has attracted venture capitalists and venture builders like MPM BioImpact, Polaris Partners, and Flagship Pioneering, as well as global pharma leaders such as Pfizer, Roche, and Johnson & Johnson. These players work closely with government agencies, like Enterprise Singapore, that drive startup development, provide patient funding, expertise, infrastructure, and networks crucial for producing globally competitive solutions.
Singapore’s strategic position as a bridge between Asian and global markets enables it to play an outsized role in driving biomedical advancements. This works both ways, as a gateway for global companies to access the growing opportunities in Asia, and as a springboard for regional companies to expand worldwide. For example, through partnerships with healthcare organisations like Cedars-Sinai and Mayo Clinic in the US, Enterprise Singapore supports Singapore startups to test and scale their solutions in overseas markets, facilitating a bi-directional flow of innovation to improve healthcare for communities.
Join Enterprise Singapore at the ‘Asia Cross Border Investments Panel’ to explore how cross-border capital, talent, and technologies are converging to drive breakthroughs in precision medicine, innovative therapies, and next-generation diagnostics. The panel will take place on January 12, 2026, from 11:00 am to 12:00 pm at RESI JPM by LSN, held at the Marriott Marquis, San Francisco. Learn from prominent industry leaders how transcontinental partnerships, including those with Singapore, are shaping the future of healthcare innovation – from discovery to global commercialisation.
To join the conversation, please contact Claire Jeong, VP of Investor Research, Asia BD, at c.jeong@lifesciencenation.com.
















